| Name | TLR7 agonist 2 |
| Description | TLR7 agonist 2 (TLR7-IN-1) is a specific and effective Toll-like Receptor 7 (TLR7) agonist (LEC=0.4 μM). |
| Cell Research | The ability of TLR7-agonist-1 to activate human TLR7 and/or TLR8 is assessed by using HEK293 cells. Briefly, HEK293 cells are grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine). Transfected cells are then detached with Trypsin-EDTA, washed in PBS and resuspended in medium to a density of 1.67×105 cells/mL. Thirty microliters of cells are then dispensed into each well in 384-well plates, where 10 μL of TLR7-agonist-1 in 4% DMSO is already present. Following 6 hours incubation at 37°C, 5% CO2, the luciferase activity is determined by adding 15 μL of Steady Lite Plus substrate to each well and readout performed on a microplate imager. Lowest effective concentrations (LEC) values are determined for TLR7-agonist-1. |
| Animal Research | In C57Bl/6 mice model,Single oral administration of 0.3, 1, 3, and 10 mg/kg doses of TLR7-agonist-1. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (133.79 mM), Sonication is recommended.
|
| Keywords | Toll-like Receptor (TLR) | TLR-7 agonist 2 | TLR7 agonist 2 | TLR7 | TLR | Inhibitor | inhibit |
| Inhibitors Related | D-Glucuronic acid | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloranil | CU-115 | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP |
| Related Compound Libraries | Nonsteroidal Anti-Inflammatory Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Antioxidant Compound Library | Pyroptosis Compound Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
